MorphoSys AG (MORG.DE)
24 Apr 2019
* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
FRANKFURT, Feb 25 German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.
BERLIN, Jan 28 The following are some of the factors that may move German stocks on Monday:
BERLIN, Nov 16 The following are some of the factors that may move German stocks on Friday: